Company / SG&A Expense
Evolent Health, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$303.9M
FY2025
5-year range
$219.5M / $358.1M
FY2021-FY2025
Trend
+15.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $161M in FY2016 to $358M in FY2023.
Based on SEC 10-K filings.
$304M in FY2025 with a 5-year CAGR of +7.6%.
Improved from $358M to $304M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +4.1%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.5% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $303.9M | +15.5% |
| FY2024 | $263.1M | -26.5% |
| FY2023 | $358.1M | +33.0% |
| FY2022 | $269.3M | +22.7% |
| FY2021 | $219.5M | +4.3% |
| FY2020 | $210.4M | -11.0% |
| FY2019 | $236.4M | +0.4% |
| FY2018 | $235.4M | +14.5% |
| FY2017 | $205.7M | +28.0% |
| FY2016 | $160.7M | +113.4% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026